Rare Diseases Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

This Phase 3 study by Pfizer focused on a gene therapy treatment for boys with Duchenne Muscular Dystrophy (DMD), a serious muscle-wasting condition. The trial, which is active but not recruiting, already has results available from multiple countries. If the treatment is effective, it could improve muscle function and slow down the progression of DMD, offering hope for better quality of life and longer mobility for patients.

Endotype DIrected Treatment for OSA in Down Syndrome

The University of Arizona is conducting this Phase 4 trial to test new medication combinations and oxygen therapy for obstructive sleep apnea (OSA) in children and adults with Down syndrome. Recruiting 200 participants across five US sites, this study aims to find personalized treatments that improve sleep quality, behavior, and cognitive function. Better management of OSA could significantly enhance daily life for individuals with Down syndrome.

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

This completed Phase 3 trial by PTC Therapeutics studied ataluren, a drug designed for Duchenne muscular dystrophy caused by nonsense mutations. With 360 participants worldwide, the trial’s results may provide insights into how ataluren helps maintain walking ability and slows disease progression. This treatment option could be important for patients seeking to extend their physical abilities.

A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc conducted this Phase 3 trial testing gene therapy called DTX401 for patients with Glycogen Storage Disease Type Ia, a rare disorder affecting glucose metabolism. The study, now fully enrolled with 49 participants, aims to reduce or eliminate the need for continuous glucose replacement therapy. Successful treatment could mean improved blood sugar control and a more normal daily routine for affected patients.

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

This Phase 3 trial by Hoffmann-La Roche tested crovalimab, a monoclonal antibody, in children with atypical hemolytic uremic syndrome, a rare kidney and blood disorder. The study is active but not recruiting and includes sites in several countries. If successful, crovalimab could offer a new, easier-to-use treatment option that may improve health outcomes for pediatric patients with aHUS who have not received complement inhibitor therapy before.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.